EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Aurora A Kinase Inhibition Is Synthetic Lethal With the Activation of MYCN in Retinoblastoma

Qili Liao, Jie Yang, Hanhan Shi, Reyizha Mengjiang, Yongyun Li, Qianqian Zhang, Xuyang Wen, Shengfang Ge, Peiwei Chai, Xianqun Fan, Renbing Jia, Jiayan Fan

Investigative Ophthalmology & Visual Science · 07.02.2025 · 66 (2) · 20

DOI: 10.1167/iovs.66.2.20 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Investigative Ophthalmology & Visual Science, erschienen am 07.02.2025. Verfasst von Qili Liao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China. Hauptthemen laut MEDLINE: Aurora Kinase A, N-Myc Proto-Oncogene Protein, Retinoblastoma, Retinal Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

RB1 inactivation and MYCN activation have been documented as common oncogenic alterations in retinoblastoma (RB). Direct targeting of RB1 and MYCN has not yet been proven to be feasible. The current treatment options for RB mainly consist of conventional chemotherapy, which inevitably poses health-threatening side effects. Here, we aimed to screen an in-house compound library to identify potential drugs for the treatment of human RB.

Methods

Aurora A kinase (AURKA) inhibitors were identified by differential viability screening with a tool compound library, and the pharmacological safety and efficacy of candidate drugs were further validated in zebrafish and RB patient-derived xenograft (PDX) models in vivo. Further CUT & Tag assay, ChIP-qPCR and RNA seq performances showed that MYCN binds to the AURKA promoter and upregulates its transcription, suggesting that AURKA inhibition induces synthetic lethality in RB.

Results

In this study, we revealed that AURKA inhibitors exhibited high therapeutic efficacy against RB both in vitro and in vivo. Mechanistically, we found that MYCN could bind to the AURKA promoter region to regulate its transcription, thereby promoting AURKA expression and consequently driving RB progression. Interestingly, AURKA inhibition exhibited synthetic lethality with RB1-deficient and MYCN-amplification in RB cells.

Conclusions

Collectively, these findings demonstrate that AURKA is crucial for RB progression and further expanded the current understanding of synthetic lethal therapeutic strategies. Our study indicates that AURKA inhibitors may represent a new therapeutic strategy for selectively targeting patients with RB with RB1-deficient and MYCN-amplification to improve the prognosis of aggressive types of patients with RB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aurora Kinase AN-Myc Proto-Oncogene ProteinRetinoblastomaRetinal NeoplasmsProtein Kinase InhibitorsGene Expression Regulation, NeoplasticSynthetic Lethal MutationsHumansAnimalsZebrafishXenograft Model Antitumor AssaysMiceCell Line, Tumor

Substanzen

Aurora Kinase AN-Myc Proto-Oncogene ProteinMYCN protein, humanAURKA protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
  • Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, People's Republic of China.
  • National Research Center for Translational Medicine (Shanghai), State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Pe…

Zitieren

APA

Liao, Q., Yang, J., Shi, H., Mengjiang, R., Li, Y., Zhang, Q., Wen, X., Ge, S., Chai, P., Fan, X., Jia, R., & Fan, J. (2025). Aurora A Kinase Inhibition Is Synthetic Lethal With the Activation of MYCN in Retinoblastoma. Investigative Ophthalmology & Visual Science, 66(2), 20. https://doi.org/10.1167/iovs.66.2.20

Vancouver

Liao Q, Yang J, Shi H, Mengjiang R, Li Y, Zhang Q, et al. Aurora A Kinase Inhibition Is Synthetic Lethal With the Activation of MYCN in Retinoblastoma. Investigative Ophthalmology & Visual Science. 2025;66(2):20. doi:10.1167/iovs.66.2.20

BibTeX
@article{Liao2025,
  author = {Liao, Qili and Yang, Jie and Shi, Hanhan and Mengjiang, Reyizha and Li, Yongyun and Zhang, Qianqian and Wen, Xuyang and Ge, Shengfang and Chai, Peiwei and Fan, Xianqun and Jia, Renbing and Fan, Jiayan},
  title = {Aurora A Kinase Inhibition Is Synthetic Lethal With the Activation of MYCN in Retinoblastoma},
  journal = {Investigative Ophthalmology & Visual Science},
  year = {2025},
  volume = {66},
  number = {2},
  pages = {20},
  doi = {10.1167/iovs.66.2.20}
}
Kostenlos starten →